ASIA-PACIFIC NEWBORN SCREENING MARKET 2019-2027

MARKET OUTLOOK
Triton Market Research's Asia-Pacific newborn screening market report has determined the market to proliferate at a CAGR of 14.38% during the forecasting period between 2019 and 2027.
India, South Korea, Japan, China, ASEAN countries, Australia & New Zealand and countries in rest of APAC together constitute the market for newborn screening in the Asia-Pacific region.
The rise of the Australia newborn screening market is backed by the government support for newborn screening. According to Mater Mothers’ Hospital, all the babies born in Australia are tested for newborn screening under the Queensland Newborn Screening Program, to search for rare, but critical medical conditions that can hamper the normal development of babies. Newborn screening tests help in early diagnosis of disorders, in order to start treatment immediately, so that severe intellectual and/or physical disabilities can be prevented. Newborn screening in Australia is performed for 26 different medical disorders, which include phenylketonuria (PKU), congenital hypothyroidism, cystic fibrosis and fatty acid oxidation disorders. Furthermore, according to the Australian Bureau of Statistics, the total number of registered births rose to 311,104 from 305,377 in 2015. This is further expected to have a positive impact on the newborn screening market, as all the babies born in Australia are given a newborn screening test for the early diagnosis of medical disorders that can negatively affect the normal development of babies.
COMPETITIVE OUTLOOK
Some of the established giants in the market include NeoGen Labs Pvt. Ltd., PerkinElmer, Inc., Trivitron Healthcare, Cardinal Health, Inc., Natus Medical, Incorporated, Waters Corporation, ZenTech S.A., Bio-Rad Laboratories, Inc., Masimo Corporation, GE Healthcare Limited, Thermo Fisher Scientific, Inc., SCIEX, BioTek Instruments, Inc., Agilent Technologies, Inc. and Medtronic Plc.

TABLE OF CONTENT
1. ASIA-PACIFIC NEWBORN SCREENING MARKET - SUMMARY
2. INDUSTRY OUTLOOK
2.1. MARKET DEFINITION
2.2. KEY INSIGHTS
2.2.1. DEMAND FOR NEWBORN SCREENING INSTRUMENTS IS RISING STEADILY
2.2.2. GROWTH IN DRY BLOOD SPOT TEST
2.2.3. TECHNIQUES USED IN NEWBORN SCREENING TESTS
2.3. EVOLUTION & TRANSITION OF NEWBORN SCREENING
2.4. PORTER’S FIVE FORCE ANALYSIS
2.4.1. THREAT OF NEW ENTRANTS
2.4.2. THREAT OF SUBSTITUTE
2.4.3. BARGAINING POWER OF SUPPLIERS
2.4.4. BARGAINING POWER OF BUYERS
2.4.5. THREAT OF COMPETITIVE RIVALRY
2.5. KEY IMPACT ANALYSIS
2.5.1. RELIABILITY
2.5.2. COST
2.5.3. AVAILABILITY
2.5.4. TECHNOLOGICAL ADVANCEMENT
2.6. MARKET ATTRACTIVENESS INDEX
2.7. VENDOR SCORECARD
2.8. INDUSTRY COMPONENTS
2.8.1. RAW MATERIAL SUPPLIERS
2.8.2. MANUFACTURERS
2.8.3. DISTRIBUTORS
2.8.4. END-USERS
2.9. REGULATORY FRAMEWORK
2.10. INDUSTRY PLAYER POSITIONING
2.11. KEY MARKET STRATEGIES
2.11.1. PRODUCT LAUNCH
2.12. MARKET DRIVERS
2.12.1. INCREASE IN OCCURRENCES OF NEWBORN DISEASES
2.12.2. GROWING NUMBER OF INFANTS WITH BIRTH DEFECT
2.12.3. BACKING OF GOVERNMENT TOWARDS NEWBORN CHILD HEALTH
2.12.4. RISING AWARENESS FOR PEDIATRIC CONGENITAL HEART DISEASE
2.13. MARKET RESTRAINTS
2.13.1. ABSENCE OF PROPER HEALTHCARE INFRASTRUCTURE FOR NEWBORN BABIES IN DEVELOPING COUNTRIES
2.13.2. SOCIO-ECONOMIC HURDLES IN THE IMPLEMENTATION OF NEWBORN CHILD SCREENING
2.14. MARKET OPPORTUNITIES
2.14.1. NEWBORN SCREENING HELPS IN EARLY IDENTIFICATION AND MANAGEMENT OF AFFECTED NEWBORNS
2.14.2. TECHNOLOGICAL ADVANCEMENTS IN NEWBORN SCREENING
2.14.3. INCREASE IN NUMBER OF PREGNANT WOMEN WITH ADVANCED MATERNAL AGE
2.15. MARKET CHALLENGES
2.15.1. DEARTH OF SKILLED PROFESSIONAL IN HEALTHCARE INDUSTRY
2.15.2. MAINTENANCE OF EQUIPMENT IN HOSPITAL
3. NEWBORN SCREENING MARKET OUTLOOK - BY PRODUCT
3.1. NEWBORN SCREENING INSTRUMENTS
3.2. NEWBORN SCREENING REAGENTS & ASSAY KITS
4. NEWBORN SCREENING MARKET OUTLOOK - BY TEST TYPE
4.1. HEARING SCREEN TEST
4.2. CRITICAL CONGENITAL HEART DISEASE (CCHD) TEST
4.3. DRY BLOOD SPOT TEST
5. NEWBORN SCREENING MARKET OUTLOOK - BY TECHNOLOGY
5.1. TANDEM MASS SPECTROMETRY
5.2. PULSE OXIMETRY
5.3. ENZYME-BASED ASSAYS
5.4. DNA-BASED ASSAYS
5.5. ELECTROPHORESIS
5.6. OTHERS
6. NEWBORN SCREENING MARKET - REGIONAL OUTLOOK
6.1. CHINA
6.2. JAPAN
6.3. INDIA
6.4. SOUTH KOREA
6.5. ASEAN COUNTRIES
6.6. AUSTRALIA & NEW ZEALAND
6.7. REST OF ASIA-PACIFIC
7. COMPETITIVE LANDSCAPE
7.1. SCIEX
7.2. BIOTEK INSTRUMENTS, INC.
7.3. BIO-RAD LABORATORIES, INC.
7.4. CARDINAL HEALTH, INC.
7.5. GE HEALTHCARE, LIMITED
7.6. AGILENT TECHNOLOGIES, INC.
7.7. MASIMO CORPORATION
7.8. NATUS MEDICAL, INCORPORATED
7.9. MEDTRONIC PLC
7.10. THERMO FISHER SCIENTIFIC, INC.
7.11. NEOGEN LABS PVT. LTD.
7.12. PERKINELMER, INC.
7.13. ZENTECH S.A.
7.14. WATERS CORPORATION
7.15. TRIVITRON HEALTHCARE
8. METHODOLOGY & SCOPE
8.1. RESEARCH SCOPE
8.2. SOURCES OF DATA
8.3. RESEARCH METHODOLOGY



LIST OF TABLES
TABLE 1: ASIA-PACIFIC NEWBORN SCREENING MARKET, BY COUNTRY, 2019-2027 (IN $ MILLION)
TABLE 2: MARKET ATTRACTIVENESS INDEX
TABLE 3: VENDOR SCORECARD
TABLE 4: REGULATORY FRAMEWORK
TABLE 5: LIST OF PRODUCT LAUNCHES
TABLE 6: INFANT MORTALITY RATE IN DEVELOPING COUNTRIES (TOTAL DEATHS/ 1000 LIVE BIRTHS)
TABLE 7: ASIA-PACIFIC NEWBORN SCREENING MARKET, BY PRODUCT, 2019-2027 (IN $ MILLION)
TABLE 8: ASIA-PACIFIC NEWBORN SCREENING MARKET, BY TEST TYPE, 2019-2027 (IN $ MILLION)
TABLE 9: ASIA-PACIFIC NEWBORN SCREENING MARKET, BY TECHNOLOGY, 2019-2027 (IN $ MILLION)
TABLE 10: ASIA-PACIFIC NEWBORN SCREENING MARKET, BY COUNTRY, 2019-2027 (IN $ MILLION)


LIST OF FIGURES
FIGURE 1: PORTER’S FIVE FORCE ANALYSIS
FIGURE 2: KEY BUYING IMPACT ANALYSIS
FIGURE 3: INDUSTRY COMPONENTS
FIGURE 4: INDUSTRY PLAYER POSITIONING IN 2018 (IN %)
FIGURE 5: FERTILITY RATE (AVERAGE BIRTHS PER WOMAN IN %) IN 2017
FIGURE 6: ASIA-PACIFIC NEWBORN SCREENING MARKET, BY NEWBORN SCREENING INSTRUMENTS, 2019-2027 (IN $ MILLION)
FIGURE 7: ASIA-PACIFIC NEWBORN SCREENING MARKET, BY NEWBORN SCREENING REAGENTS & ASSAY KITS, 2019-2027 (IN $ MILLION)
FIGURE 8: ASIA-PACIFIC NEWBORN SCREENING MARKET, BY HEARING SCREEN TEST, 2019-2027 (IN $ MILLION)
FIGURE 9: ASIA-PACIFIC NEWBORN SCREENING MARKET, BY CRITICAL CONGENITAL HEART DISEASE (CCHD) TEST, 2019-2027 (IN $ MILLION)
FIGURE 10: ASIA-PACIFIC NEWBORN SCREENING MARKET, BY DRY BLOOD SPOT TEST, 2019-2027 (IN $ MILLION)
FIGURE 11: ASIA-PACIFIC NEWBORN SCREENING MARKET, BY TANDEM MASS SPECTROMETRY, 2019-2027 (IN $ MILLION)
FIGURE 12: ASIA-PACIFIC NEWBORN SCREENING MARKET, BY PULSE OXIMETRY, 2019-2027 (IN $ MILLION)
FIGURE 13: ASIA-PACIFIC NEWBORN SCREENING MARKET, BY ENZYME-BASED ASSAY, 2019-2027 (IN $ MILLION)
FIGURE 14: ASIA-PACIFIC NEWBORN SCREENING MARKET, BY DNA-BASED ASSAYS, 2019-2027 (IN $ MILLION)
FIGURE 15: ASIA-PACIFIC NEWBORN SCREENING MARKET, BY ELECTROPHORESIS, 2019-2027 (IN $ MILLION)
FIGURE 16: ASIA-PACIFIC NEWBORN SCREENING MARKET, BY OTHERS, 2019-2027 (IN $ MILLION)
FIGURE 17: ASIA-PACIFIC NEWBORN SCREENING MARKET, REGIONAL OUTLOOK, 2018 & 2027 (IN %)
FIGURE 18: CHINA NEWBORN SCREENING MARKET, 2019-2027 (IN $ MILLION)
FIGURE 19: JAPAN NEWBORN SCREENING MARKET, 2019-2027 (IN $ MILLION)
FIGURE 20: INDIA NEWBORN SCREENING MARKET, 2019-2027 (IN $ MILLION)
FIGURE 21: SOUTH KOREA NEWBORN SCREENING MARKET, 2019-2027 (IN $ MILLION)
FIGURE 22: ASEAN COUNTRIES NEWBORN SCREENING MARKET, 2019-2027 (IN $ MILLION)
FIGURE 23: AUSTRALIA & NEW ZEALAND NEWBORN SCREENING MARKET, 2019-2027 (IN $ MILLION)
FIGURE 24: REST OF ASIA-PACIFIC NEWBORN SCREENING MARKET, 2019-2027 (IN $ MILLION)